Compare DexCom, Inc. (DXCM) vs iShares 10 20 Year Treasury Bond ETF (TLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs iShares 10 20 Year Treasury Bond ETF — how do they compare? DexCom, Inc. trades at $90.64 (market cap $33.79B), while iShares 10 20 Year Treasury Bond ETF trades at $96.56. The key difference: DexCom, Inc. is trading nearer its 52-week high, iShares 10 20 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| DXCM | TLH | |
|---|---|---|
Market Cap | $33.79B | — |
Sector | Health | Fixed Income |
52-Week High | $89.53 | $105.36 |
52-Week Low | $54.84 | $96.39 |
Enterprise Value | $33.24B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
TLH trades at $96.62 with minimal daily movement (+0.24%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. The stock faces resistance at $97 and support at $96. Recent dividend payments of $0.38, $0.36, and $0.41 in mid-2026 indicate ongoing shareholder returns despite the challenging technical backdrop.
The outlook remains cautious with bearish technical signals dominating. Key resistance at $97 must be breached for bullish momentum. Dividend consistency provides some stability, but the lack of fundamental data and weak technical structure suggests limited near-term upside potential for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About iShares 10 20 Year Treasury Bond ETF
TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.
Read more on TLH →
